Botox made by Allergan
Anti-wrinkle medicines Dysport (L), Botox (C) and Xeomin (R) are displayed in an examination room at the office of Howard Sobel, attending dermatologist and dermatologic surgeon at Lenox Hill Hospital in New York on March 22, 2013. Reuters/Mike Segar

(Reuters) - Valeant Pharmaceuticals International Inc said it is prepared to improve its offer for Allergan Inc to at least $200 per share.

The Botox maker's shares closed at $184.21 on Friday.

Valeant Chief Executive Michael Pearson said in a letter to Allergan's board that Allergan's stock would not be trading at the multiples it is now if it were not for Valeant's offer.

Pearson told Reuters last week that a possible revised stock-and-cash bid would be worth more than $200 per share, assuming that Valeant's stock rises, and would include more cash.

RELATED STORIES